Vancomycin is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 5 US drug patents filed from 2021 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 06, 2035. Details of Vancomycin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11517609 | Glycopeptide compositions |
Nov, 2035
(9 years from now) | Active |
| US10849956 | Glycopeptide compositions |
Nov, 2035
(9 years from now) | Active |
| US11000567 | Glycopeptide compositions |
Nov, 2035
(9 years from now) | Active |
| US10188697 | Glycopeptide compositions |
Nov, 2035
(9 years from now) | Active |
| US10039804 | Glycopeptide compositions |
Nov, 2035
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Vancomycin's patents.
Latest Legal Activities on Vancomycin's Patents
Given below is the list of recent legal activities going on the following patents of Vancomycin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Feb, 2026 | US10039804 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Oct, 2024 | US11000567 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 28 Dec, 2022 | US11000567 |
| Email Notification
Critical | 28 Dec, 2022 | US10188697 |
| Email Notification
Critical | 28 Dec, 2022 | US10039804 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 28 Dec, 2022 | US10039804 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 28 Dec, 2022 | US10188697 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 28 Dec, 2022 | US10849956 |
| Email Notification
Critical | 28 Dec, 2022 | US10849956 |
Several oppositions have been filed on Vancomycin's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Vancomycin's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Vancomycin patents.
Vancomycin's Oppositions Filed in EPO
Vancomycin has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15791287A | Oct, 2020 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Revoked |
US patents provide insights into the exclusivity only within the United States, but
Vancomycin is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Vancomycin's family patents as well as insights into
ongoing legal events
on those patents.
Vancomycin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vancomycin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Vancomycin's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 06, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vancomycin Generics:
There are no approved generic versions for Vancomycin as of now.
Alternative Brands for Vancomycin
Vancomycin which is used for treating bacterial infections., has several other brand drugs in the same treatment category and using the same active ingredient (Vancomycin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Apotex |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi |
| |||||
| Wyeth Pharms |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Vancomycin. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Azurity |
| |
| Hikma |
|
About Vancomycin
Vancomycin is a drug owned by Hikma Pharmaceuticals Usa Inc. It is used for treating bacterial infections. Vancomycin uses Vancomycin as an active ingredient. Vancomycin was launched by Hikma in 2021.
Approval Date:
Vancomycin was approved by FDA for market use on 26 August, 2021.
Active Ingredient:
Vancomycin uses Vancomycin as the active ingredient. Check out other Drugs and Companies using Vancomycin ingredient
Treatment:
Vancomycin is used for treating bacterial infections.
Dosage:
Vancomycin is available in solution form for intravenous, oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5GM/100ML (50MG/ML) | SOLUTION | Discontinued | INTRAVENOUS, ORAL |